CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. A CARM1 Inhibitor Potently Suppresses Breast Cancer Both In Vitro and In Vivo.Journal of medicinal chemistry · 2024
   Article
2. CARM1 promotes gastric cancer progression by regulating TFE3 mediated autophagy enhancement through the cytoplasmic AMPK-mTOR and nuclear AMPK-CARM1-TFE3 signaling pathways.Cancer cell international · 2022
   Article
3. PFKFB4 promotes lung adenocarcinoma progression via phosphorylating and activating transcriptional coactivator SRC-2.BMC pulmonary medicine · 2021
   Article
4. Convergent organization of aberrant MYB complex controls oncogenic gene expression in acute myeloid leukemia.eLife · 2021
   Article
5. PRMT6 serves an oncogenic role in lung adenocarcinoma via regulating p18.Molecular medicine reports · 2020
   Article

Corrections and comments

• Erratum for
  CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis.2018

Authors and funding

25 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.